Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Return on Equity (2016 - 2025)

Historic Return on Equity for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Q3 2025 value amounting to 1.14%.

  • Enanta Pharmaceuticals' Return on Equity fell 3000.0% to 1.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.14%, marking a year-over-year decrease of 3000.0%. This contributed to the annual value of 0.85% for FY2025, which is 1700.0% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Return on Equity of 1.14% as of Q3 2025, which was down 3000.0% from 1.06% recorded in Q2 2025.
  • Enanta Pharmaceuticals' Return on Equity's 5-year high stood at 0.2% during Q1 2021, with a 5-year trough of 1.14% in Q3 2025.
  • For the 5-year period, Enanta Pharmaceuticals' Return on Equity averaged around 0.57%, with its median value being 0.52% (2023).
  • In the last 5 years, Enanta Pharmaceuticals' Return on Equity tumbled by -900bps in 2022 and then tumbled by -3300bps in 2025.
  • Enanta Pharmaceuticals' Return on Equity (Quarter) stood at 0.29% in 2021, then crashed by -32bps to 0.39% in 2022, then tumbled by -75bps to 0.68% in 2023, then dropped by -29bps to 0.87% in 2024, then crashed by -30bps to 1.14% in 2025.
  • Its last three reported values are 1.14% in Q3 2025, 1.06% for Q2 2025, and 0.94% during Q1 2025.